1. A grafted polymer comprising the following moiety
wherein:
p represents an integer greater than 0,
each R1, identical or different, represents a hydrogen atom or a C1-4 alkyl group,
each R2, identical or different, represents a OH or NH2 group,
each R3, identical or different, represents a C2-180 alkyl group, optionally substituted with one or more C1-4 alkyl substituents,
L represents a C1-6 alkylene group, and
n and m each independently represent an integer between 0 and 3200, m+n is between 1 and 3500, the ratio between m and n being between 0.011 and 0.11.
2. A composition suitable for the preparation of liquid crystal films, said composition comprising a liquid crystal dispersed in a grafted polymer according to claim 1.
3. The composition according to claim 2, comprising at least one solvent and optionally at least one surfactant.
4. The composition according to claim 3, wherein said solvent is water.
5. The composition according to claim 2, wherein the liquid crystal is selected from the substituted biphenyls or triphenyls compounds family.
6. The composition according to claim 2, wherein the liquid crystal is in proportion of from 20 to 60% by weight of the composition.
7. The composition according to claim 2, wherein the grafted polymer is in proportion of from 10 to 40% by weight of the composition.
8. The composition according to claim 3, wherein the solvent is in proportion of from 10 to 40% by weight of the composition.
9. The composition according to claim 3, wherein the surfactant is in proportion of from 0 to 10% by weight of the composition.
10. A film formed from the composition according to claim 2.
11. A liquid crystal device comprising a film according to claim 10, said film being provided on a substrate.
12. The device according to claim 11, further comprising a second substrate, wherein the film is provided between both substrates.
13. The device according to claim 11, wherein the substrate is made of glass or plastic.
14. The device according to claim 12, further comprising an electrode layer on each substrate, in an adjacent position to the film.
15. An electro-optical system comprising a PDLC film provided between two electrode layers, said PDLC film comprising one or more liquid crystals forming microdroplets in a polymer matrix, said polymer matrix comprising a grafted polymer according to claim 1.
16. An electro-optical glazing comprising
a PDLC film provided between two transparent plates, said PDLC film comprising one or more liquid crystals forming microdroplets in a polymer matrix, said polymer matrix comprising a grafted polymer according to claim 1.
17. The electro-optical glazing according to claim 16, further comprising an electrode layer on each plate, in an adjacent position to said PDLC film.
18. The electro-optical glazing according to claim 16, wherein said plates are made of glass or plastic.
19. A window comprising a glazing according to claim 16.
20. A door comprising a glazing according to claim 16.
21. A roof comprising a glazing according to claim 16.
22. Glass comprising a glazing according to claim 16.
23. A method for the preparation of a product usually opaque that becomes transparent under the application of an electric field, comprising the steps of:
dispersing at least one liquid crystal in a grafted polymer according to claim 1.
24. The grafted polymer according to claim 1, wherein each R3, identical or different, represents a C4-50 alkyl group, optionally substituted with one or more C1-4 alkyl substituents.
25. The grafted polymer according to claim 1, wherein each R3, identical or different, represents a C6-20 alkyl, optionally substituted with one or more C1-4 alkyl substituents.
26. The grafted polymer according to claim 1, wherein m+n is between 1 and 150.
27. The grafted polymer according to claim 1, wherein the ratio between m and n is between 0.011 and 0.051.
28. The composition according to claim 6, wherein the liquid crystal is in proportion of from 20 to 40% by weight of the composition.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-39. (canceled)
40. A method of diagnosing a p115-HT receptor related disorders in a subject comprising determining the level of p11 in a biological sample wherein said sample comprises peripheral blood mononuclear cells from said subject and comparing said p11 level to a reference, wherein an abnormal level of p11 compared to the reference constitutes a positive diagnosis of p115-HT receptor related disorder.
41. The method according to claim 40, wherein said peripheral blood mononuclear cells are NK cells andor CD-8+ T-cells.
42. The method according to claim 40, wherein said peripheral blood mononuclear cells are NK cells.
43. The method according to claim 40, wherein said p115-HT receptor related disorder is depression.
44. The method according to claim 43, wherein said depression comprises a p11 associated depression.
45. The method according to claim 40, wherein said p115-HT receptor related disorder is a disorder associated with an abnormally low level of p11, wherein reduced level of p11 in a subject compared to a control subject constitutes a positive diagnosis of such disorders.
46. The method according to claim 45, wherein said disorder associated with an abnormally low level of p11 is selected from a group consisting of depression, obsessive compulsive disorder, drug addiction, eating disorders, Alzheimer’s disease, attention deficit disorder and attention deficit hyperactive disorder.
47. The method according to claim 40, wherein said p115-HT receptor related disorders are disorders associated with an abnormally high level of p11, wherein an elevated level of p11 in a subject compared to that in a control subject constitutes a positive diagnosis of such disorders.
48. The method according to claim 47, wherein said disorder associated with an abnormally high level of p11 is selected from a group consisting of mania, dipolar disorder, anxiety disorders, aggression, sleep disorders, sexual dysfunction and gastrointestinal disorders.
49. The method according to claim 40, wherein said level of p11 is determined by assaying p11 protein level in the monocytes andor lymphocytes in said biological sample from said subject.
50. The method according to claim 40, wherein said level of p11 is determined by assaying p11 mRNA level in a biological sample from said subject.
51. The method of claim 40, wherein the level of p11 is determined using a monoclonal antibody specific for p11.
52. The method of claim 50, wherein the detection of said monoclonal antibody is achieved by using standard ELISA, FACS analysis, andor standard imaging techniques.